1. Cell Cycle/DNA Damage Autophagy Apoptosis Metabolic Enzyme/Protease
  2. Nucleoside Antimetabolite/Analog Autophagy Apoptosis Endogenous Metabolite
  3. Adenosine

Adenosine  (Synonyms: 腺苷; Adenine riboside; D-Adenosine)

目录号: HY-B0228 纯度: 99.96%
COA 产品使用指南 技术支持

Adenosine (Adenine riboside) 是一种普遍存在的内源性分泌物,是通过四种G蛋白偶联受体(A1、A2A、A2B 和 A3)的起作用。Adenosine 几乎影响细胞生理学的所有方面,包括神经元活动、血管功能、血小板聚集和血细胞调节。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Adenosine

Adenosine Chemical Structure

CAS No. : 58-61-7

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥126
In-stock
100 mg ¥115
In-stock
500 mg ¥350
In-stock
1 g ¥465
In-stock
5 g ¥650
In-stock
10 g ¥850
In-stock
25 g ¥1150
In-stock
50 g ¥1495
In-stock
100 g ¥1944
In-stock
> 100 g   询价  

* Please select Quantity before adding items.

Customer Review

    Adenosine purchased from MCE. Usage Cited in: Int J Mol Med. 2016 Sep;38(3):969-75.  [Abstract]

    Effects of Adenosine and CGS21680 on CD39 and CD73 expression. (A) Adenosine and CGS21680 promote the expression of CD39. (B) Adenosine and CGS21680 promote the expression of CD73. GAPDH is used as an internal reference.
    • 生物活性

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation[1][2].

    IC50 & Target

    Human Endogenous Metabolite

     

    Microbial Metabolite

     

    细胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A-431 IC50
    195 μM
    Compound: Adenosine
    Inhibition of erbB-1 receptor tyrosine kinase from A431 human epidermoid carcinoma cells
    Inhibition of erbB-1 receptor tyrosine kinase from A431 human epidermoid carcinoma cells
    [PMID: 9089334]
    CHO EC50
    0.29 μM
    Compound: adenosine
    Agonist activity at human adenosine A3 receptor expressed in CHO cells assessed as increase of intracellular calcium level
    Agonist activity at human adenosine A3 receptor expressed in CHO cells assessed as increase of intracellular calcium level
    [PMID: 20541935]
    CHO EC50
    0.29 μM
    Compound: adenosine
    Agonist activity at human adenosine A3 receptor expressed in CHO cells
    Agonist activity at human adenosine A3 receptor expressed in CHO cells
    [PMID: 21388809]
    CHO EC50
    0.31 μM
    Compound: adenosine
    Agonist activity at human adenosine A1 receptor expressed in CHO cells assessed as increase of intracellular calcium level
    Agonist activity at human adenosine A1 receptor expressed in CHO cells assessed as increase of intracellular calcium level
    [PMID: 20541935]
    CHO EC50
    0.31 μM
    Compound: adenosine
    Agonist activity at human adenosine A1 receptor expressed in CHO cells
    Agonist activity at human adenosine A1 receptor expressed in CHO cells
    [PMID: 21388809]
    CHO EC50
    0.7 μM
    Compound: adenosine
    Agonist activity at human adenosine A2A receptor expressed in CHO cells assessed as increase of intracellular calcium level
    Agonist activity at human adenosine A2A receptor expressed in CHO cells assessed as increase of intracellular calcium level
    [PMID: 20541935]
    CHO EC50
    0.7 μM
    Compound: adenosine
    Agonist activity at human adenosine A2A receptor expressed in CHO cells
    Agonist activity at human adenosine A2A receptor expressed in CHO cells
    [PMID: 21388809]
    CHO EC50
    23500 nM
    Compound: AR-1
    Agonist activity at human adenosine A2B receptor transfected in CHO cells assessed as changes in cAMP formation in the presence of nitrobenzylthioinosine
    Agonist activity at human adenosine A2B receptor transfected in CHO cells assessed as changes in cAMP formation in the presence of nitrobenzylthioinosine
    [PMID: 26356532]
    CHO EC50
    24 μM
    Compound: adenosine
    Agonist activity at human adenosine A2B receptor expressed in CHO cells assessed as increase of intracellular calcium level
    Agonist activity at human adenosine A2B receptor expressed in CHO cells assessed as increase of intracellular calcium level
    [PMID: 20541935]
    CHO EC50
    24 μM
    Compound: adenosine
    Agonist activity at human adenosine A2B receptor expressed in CHO cells
    Agonist activity at human adenosine A2B receptor expressed in CHO cells
    [PMID: 21388809]
    CHO EC50
    290 nM
    Compound: AR-1
    Agonist activity at human adenosine A3 receptor transfected in CHO cells assessed as changes in cAMP formation in the presence of nitrobenzylthioinosine
    Agonist activity at human adenosine A3 receptor transfected in CHO cells assessed as changes in cAMP formation in the presence of nitrobenzylthioinosine
    [PMID: 26356532]
    CHO EC50
    310 nM
    Compound: AR-1
    Agonist activity at human adenosine A1 receptor transfected in CHO cells assessed as changes in cAMP formation in the presence of nitrobenzylthioinosine
    Agonist activity at human adenosine A1 receptor transfected in CHO cells assessed as changes in cAMP formation in the presence of nitrobenzylthioinosine
    [PMID: 26356532]
    CHO EC50
    730 nM
    Compound: AR-1
    Agonist activity at human adenosine A2A receptor transfected in CHO cells assessed as changes in cAMP formation in the presence of nitrobenzylthioinosine
    Agonist activity at human adenosine A2A receptor transfected in CHO cells assessed as changes in cAMP formation in the presence of nitrobenzylthioinosine
    [PMID: 26356532]
    COS-7 EC50
    1.04 μM
    Compound: adenosine
    Activity against human wild type adenosine A3 receptor expressed in COS7 cells as measured by accumulation of inositol phosphate by PLC assay
    Activity against human wild type adenosine A3 receptor expressed in COS7 cells as measured by accumulation of inositol phosphate by PLC assay
    [PMID: 16640329]
    Detroit 98 ED50
    0.08 μM
    Compound: 2
    Concentration that inhibited the growth of cultured human detroit 98 cells.
    Concentration that inhibited the growth of cultured human detroit 98 cells.
    [PMID: 7131482]
    HEK-293T EC50
    0.039 μM
    Compound: Adenosine
    Agonist activity at human A1AR expressed in HEK293T/17 cells assessed as inhibition of isoproterenol-induced cAMP accumulation incubated for 10 mins by luciferase reporter assay
    Agonist activity at human A1AR expressed in HEK293T/17 cells assessed as inhibition of isoproterenol-induced cAMP accumulation incubated for 10 mins by luciferase reporter assay
    [PMID: 22738238]
    HEp-2 IC50
    0.7 μM
    Compound: 1
    Compound was evaluated for cytotoxicity against H.Ep.-2 cells, and concentration required to inhibit the growth of treated cells to 50% of untreated control.
    Compound was evaluated for cytotoxicity against H.Ep.-2 cells, and concentration required to inhibit the growth of treated cells to 50% of untreated control.
    [PMID: 6708054]
    HEp-2 IC50
    20 μM
    Compound: 1
    Compound was evaluated for cytotoxicity against H.Ep.-2 (AK-) cells and concentration required to inhibit the growth of treated cells to 50% of untreated control
    Compound was evaluated for cytotoxicity against H.Ep.-2 (AK-) cells and concentration required to inhibit the growth of treated cells to 50% of untreated control
    [PMID: 6708054]
    HeLa IC50
    10.8 μM
    Compound: 37
    Inhibition of cytopathogenicity of herpes simplex type 1 virus (HSV-1)(KOS) in Hela cell culture.
    Inhibition of cytopathogenicity of herpes simplex type 1 virus (HSV-1)(KOS) in Hela cell culture.
    [PMID: 7473592]
    HeLa IC50
    98.85 μM
    Compound: 37
    Concentration required to cause microscopically visible change or disruption in about 50% of Hela cell sheet.
    Concentration required to cause microscopically visible change or disruption in about 50% of Hela cell sheet.
    [PMID: 7473592]
    HepG2 IC50
    18.46 μM
    Compound: 35
    Inhibition of PCSK9 mRNA expression in human HepG2 cells by SYBR Green I dye-based qRT-PCR analysis
    Inhibition of PCSK9 mRNA expression in human HepG2 cells by SYBR Green I dye-based qRT-PCR analysis
    [PMID: 30448414]
    L1210 EC50
    1.869 mM
    Compound: 2
    Antitumor activity against mouse L1210 cells assessed as inhibition of [3H]thymidine incorporation after 72 hrs
    Antitumor activity against mouse L1210 cells assessed as inhibition of [3H]thymidine incorporation after 72 hrs
    [PMID: 24915876]
    L1210 IC50
    0.991 mM
    Compound: 2
    Cytotoxicity against mouse L1210 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
    Cytotoxicity against mouse L1210 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
    [PMID: 24915876]
    L929 ED50
    0.3 μM
    Compound: 2
    Concentration that inhibited the growth of Mouse L cells.
    Concentration that inhibited the growth of Mouse L cells.
    [PMID: 7131482]
    PBMC IC50
    1.867 mM
    Compound: 2
    Cytotoxicity against human PBMC assessed as inhibition of cell viability after 72 hrs by MTT assay
    Cytotoxicity against human PBMC assessed as inhibition of cell viability after 72 hrs by MTT assay
    [PMID: 24915876]
    RAW264.7 IC50
    > 10 μM
    Compound: 19
    Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 24 hrs by Griess assay
    Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 24 hrs by Griess assay
    [PMID: 28499733]
    U2OS EC50
    63 μM
    Compound: 60961
    Inhibition of the equilibrative nucleoside transporter (ENT1, SLC29A1) as assessed by GPCR-mediated changes in cell morphology using the impedance-based transporter activity through receptor activation (TRACT) assay (PubChem AID: 1745861)
    Inhibition of the equilibrative nucleoside transporter (ENT1, SLC29A1) as assessed by GPCR-mediated changes in cell morphology using the impedance-based transporter activity through receptor activation (TRACT) assay (PubChem AID: 1745861)
    [PMID: 31551431]
    体外研究
    (In Vitro)

    Adenosine (腺嘌呤核苷) 作用于四种 G 蛋白偶联受体:其中两种,A1 和 A3,主要与 Gi 家族 G 蛋白偶联;其中两个,A2A 和 A2B,主要像 G 蛋白一样与 G 偶联。这些受体被包括咖啡因在内的黄嘌呤所拮抗。通过这些受体,它影响许多细胞和器官,通常具有细胞保护功能[2]
    Adenosine 是一种细胞外信号分子,由其前体分子 5'-三磷酸 Adenosine (ATP) 生成) 和 5'-单磷酸 Adenosine (AMP)[3]
    Adenosine 是 ATP 的常见代谢产物,在高浓度下表现出细胞毒性作用。Adenosine (1.0-4.0 mM;12-24 小时) 抑制细胞活力并触发 HepG2 细胞内质网应激[4]
    Adenosine 可诱导多种癌细胞凋亡。Adenosine (2.0 mM;12-24 小时) 在 HepG2 细胞中诱导自噬。在 HepG2 细胞系中,Adenosine 诱导的 AMPK/mTOR 通路激活部分阻断了 ER 应激并减少了凋亡细胞死亡[4]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    分子量

    267.24

    Formula

    C10H13N5O4

    CAS 号
    性状

    固体

    颜色

    White to off-white

    中文名称

    腺苷

    结构分类
    初始来源
    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    溶解性数据
    细胞实验: 

    DMSO 中的溶解度 : 33.33 mg/mL (124.72 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

    H2O 中的溶解度 : ≥ 6.67 mg/mL (24.96 mM)

    * "≥" means soluble, but saturation unknown.

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 3.7420 mL 18.7098 mL 37.4195 mL
    5 mM 0.7484 mL 3.7420 mL 7.4839 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

    * 备注:如您选择水作为储备液,请稀释至工作液后,再用 0.22 μm 的滤膜过滤除菌后使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验:

    以下溶解方案,请直接配制工作液。建议现用现配,在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶。

    • 方案 一

      请依序添加每种溶剂: PBS

      Solubility: 6.67 mg/mL (24.96 mM); 澄清溶液; 超声助溶 (<60°C)

    动物溶解方案计算器
    请输入动物实验的基本信息:

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    由于实验过程有损耗,建议您多配一只动物的量
    计算结果
    工作液所需浓度 : mg/mL
    纯度 & 产品资料

    纯度: 99.96%

    参考文献

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 3.7420 mL 18.7098 mL 37.4195 mL 93.5489 mL
    5 mM 0.7484 mL 3.7420 mL 7.4839 mL 18.7098 mL
    10 mM 0.3742 mL 1.8710 mL 3.7420 mL 9.3549 mL
    15 mM 0.2495 mL 1.2473 mL 2.4946 mL 6.2366 mL
    20 mM 0.1871 mL 0.9355 mL 1.8710 mL 4.6774 mL
    DMSO 25 mM 0.1497 mL 0.7484 mL 1.4968 mL 3.7420 mL
    30 mM 0.1247 mL 0.6237 mL 1.2473 mL 3.1183 mL
    40 mM 0.0935 mL 0.4677 mL 0.9355 mL 2.3387 mL
    50 mM 0.0748 mL 0.3742 mL 0.7484 mL 1.8710 mL
    60 mM 0.0624 mL 0.3118 mL 0.6237 mL 1.5591 mL
    80 mM 0.0468 mL 0.2339 mL 0.4677 mL 1.1694 mL
    100 mM 0.0374 mL 0.1871 mL 0.3742 mL 0.9355 mL

    * 备注:如您选择水作为储备液,请稀释至工作液后,再用 0.22 μm 的滤膜过滤除菌后使用。

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称:

     

    * 需求量:

    * 客户姓名:

     

    * Email:

    * 电话:

     

    * 公司或机构名称:

       留言给我们:

    Bulk Inquiry

    Inquiry Information

    产品名称:
    Adenosine
    目录号:
    HY-B0228
    需求量: